Related Experiment Video

Updated: Jun 15, 2026

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial

Shinji Abe1, Yoshitsugu Seo, Hiroki Hayashi

  • 1Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, Japan. sabe@nms.ac.jp

Blood Purification
|February 27, 2010
PubMed
Abstract

Insights

Polymyxin B-immobilized fiber (PMX) treatment effectively removes neutrophils in patients with acute exacerbation of interstitial pneumonia (IP). This study suggests PMX therapy may be a viable treatment option for IP exacerbations.

Area of Science:

  • Pulmonary Medicine
  • Critical Care
  • Immunology

Background:

  • Polymyxin B-immobilized fiber (PMX) treatment shows promise for acute lung injury and idiopathic pulmonary fibrosis exacerbations.
  • The precise mechanism of PMX in acute exacerbation of interstitial pneumonia (IP) requires further elucidation.

Purpose of the Study:

  • To investigate the mechanism of PMX treatment in patients experiencing acute exacerbation of interstitial pneumonia (IP).
  • To identify cellular components adsorbed by PMX during treatment for IP exacerbation.

Main Methods:

  • A pilot study involving sixteen consecutive IP patients with acute exacerbation.
  • PMX treatment administered daily for two consecutive days.
  • Analysis of adsorbed cells via electron microscopy and flow cytometry for surface markers.
  • Measurement of serum matrix metalloproteinase (MMP)-9 levels pre- and post-treatment.

Main Results:

  • Neutrophils were identified as the primary cells adsorbed by the PMX filter.
  • Adsorbed neutrophils exhibited high expression of HLA-DR, CD14, CD62L, and CD114.
  • Significant reduction in serum MMP-9 levels was observed following PMX treatment.

Conclusions:

  • PMX treatment effectively adsorbs neutrophils in acute exacerbation of interstitial pneumonia (IP).
  • This pilot study highlights the potential clinical utility of PMX therapy for managing IP exacerbations.

More Related Videos

A Set of Screening Techniques for a Quick Overview of the Neutrophil Function12:27

A Set of Screening Techniques for a Quick Overview of the Neutrophil Function

Published on: February 9, 2024

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...